Page 57 - CASA Bulletin of Anesthiology 2021, Vol 8, No. 6 (1)

Vol. 8, No. 6, 2021

34. Agrawal A, Lynskey MT. The genetic epidemiology of cannabis use, abuse and dependence. Addiction.
2006;101(6):801-812. doi:10.1111/j.1360-0443.2006.01399.x
35. Ehlers CL, Gizer IR, Vieten C, et al. Cannabis dependence in the San Francisco Family Study: age of onset of
use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35(2):102-110.
doi:10.1016/j.addbeh.2009.09.009
36. Verweij KJ, Agrawal A, Nat NO, et al. A genetic perspective on the proposed inclusion of cannabis withdrawal
in DSM-5. Psychol Med. 2013;43(8):1713-1722. doi:10.1017/S0033291712002735
37. Cornelius JR, Chung T, Martin C, Wood DS, Clark DB. Cannabis withdrawal is common among treatment-
seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to
dependence. Addict Behav. 2008;33(11):1500-1505. doi:10.1016/j.addbeh.2008.02.001
38. Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and
Withdrawal. Neuropsychopharmacology. 2018;43(1):173-194. doi:10.1038/npp.2017.212
39. Navarrete F, Aracil-Fernández A, Manzanares J. Cannabidiol regulates behavioural alterations and gene
expression changes induced by spontaneous cannabinoid withdrawal. Br J Pharmacol. 2018;175(13):2676-2688.
doi:10.1111/bph.14226Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence.
Cochrane Database Syst Rev. 2019;1(1):CD008940. Published 2019 Jan 28.
doi:10.1002/14651858.CD008940.pub3
40. Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database
Syst Rev. 2019;1(1):CD008940. Published 2019 Jan 28. doi:10.1002/14651858.CD008940.pub3
41. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during
marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155(2):171-179.
doi:10.1007/s002130000657
42. Gray KM, Watson NL, Carpenter MJ, Larowe SD. N-acetylcysteine (NAC) in young marijuana users: an open-
label pilot study. Am J Addict. 2010;19(2):187-189. doi:10.1111/j.1521-0391.2009.00027.x
43. Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in
cannabis-dependent adolescents [published correction appears in Am J Psychiatry. 2012 Aug 1;169(8):869].
Am J Psychiatry. 2012;169(8):805-812. doi:10.1176/appi.ajp.2012.12010055
44. Gray KM, Sonne SC, McClure EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for
cannabis use disorder in adults. Drug Alcohol Depend. 2017;177:249-257.
doi:10.1016/j.drugalcdep.2017.04.020
45. Danovitch I, Gorelick DA. State of the art treatments for cannabis dependence. Psychiatr Clin North Am.
2012;35(2):309-326. doi:10.1016/j.psc.2012.03.003
46. Sherman BJ, McRae-Clark AL. Treatment of Cannabis Use Disorder: Current Science and Future Outlook.
Pharmacotherapy. 2016;36(5):511-535. doi:10.1002/phar.1747

P a g e 56 | 69